Medivation


Janney Capital Keeps Buy On Medivation Following Label Expansion On Xtandi

In a research report pubished yesterday, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation (NASDAQ:MDVN) with a $110 fair value, …

Brean Capital Reiterates Buy On Medivation Following FDA Approval Of Xtandi For Pre-Chemo mCRPC

In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation (NASDAQ:MDVN) with a price target of …

Medivation Remains One Of Our Top Ideas, Says Janney Capital

In a research report released August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 …

Maxim Maintains Buy On Medivation As Xtandi Continues To Exceed Expectations

In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Medivation (MDVN) with a $112 price target. The report follows Medivation’s partner Astellas (ALPMY) second quarter results that included US …

Janney Reiterates Buy On Medivation Following Astellas’ Xtandi Sales Report; Sees $110 Fair Value

In a research report issued Friday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 fair value estimate, following Medivation’s partner Astellas (ALPMY) second quarter results …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts